The experimental therapy Bravyl significantly reduced the spread of toxic TDP-43 protein clumps in a cell model of ALS.

Shelby Kinsey lives with a rare, fast-progressing form of ALS — but she has to spend her precious time fighting for insurance ...

VectorY Therapeutics appoints Jim Scibetta as CEO to lead development of VTx-002, a vectorized antibody therapy targeting TDP ...

If you receive a denial letter from your insurer, don’t appeal the decision before seeking legal advice, says a leading ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...

The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...

VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces ...

Research Grants and 7 Development Awards for Fellowship Trainees Will Fund Critical Research Across Multiple Neuromuscular ...

Amyotrophic lateral sclerosis (ALS) is a rare neurological disorder that affects specific nerve cells in the spinal cord known as motor neurons. Symptoms involve issues with swallowing and speech ...

The global amyotrophic lateral sclerosis treatment market size was US$ 637.2 million in 2021. The global amyotrophic lateral sclerosis treatment market is forecast to grow to US$ 918 million by 2030, ...